Abstract:Background Rifampicin (RIF) is a key first-line drug used to treat tuberculosis, a primarily pulmonary disease caused by Mycobacterium tuberculosis . RIF resistance is caused by mutations in rpoB , at the cost of slower growth and reduced transcription efficiency. Antibiotic resistance to RIF is prevalent despite this fitness cost. Compensatory mutations in rpoABC genes have been shown to alleviate the fitness cost of rpoB :S450L, explaining how RIF resistant strains harbor this mutation can spread so rapidly. Unfortunately, the full set of RIF compensatory mutations is still unknown, particularly those compensating for rarer RIF resistance mutations. Objectives We performed an association study on a globally representative set of 4,309 whole genome sequenced clinical M. tuberculosis isolates to identify novel putative compensatory mutations, determine the prevalence of known and previously reported putative compensatory mutations, and determine which RIF resistance markers associate with these compensatory mutations. Results and conclusions Of the 1,079 RIF resistant isolates, 638 carried previously reported putative and high-probability compensatory mutations. Our strict criteria identified 46 additional mutations in rpoABC for which no strong prior evidence of their compensatory role exists. Of these, 35 have previously been reported. As such, our independent corroboration adds to the mounting evidence that these 35 also carry a compensatory role. The remaining 11 are novel putative compensatory markers, reported here for the first time. Six of these 11 novel putative compensatory mutations had two or more mutation events. Most compensatory mutations appear to be specifically compensating for the fitness loss due to rpoB :S450L. However, an outbreak of 22 closely related isolates each carried three rpoB mutations, the rare RIF R markers D435G and L452P and the putative compensatory mutation I1106T. This suggests compensation may require specific combinations of rpoABC mutations. Here, we report only mutations that met our very strict criteria. It is highly likely that many additional rpoABC mutations compensate for rare resistance-causing mutations and therefore did not carry the statistical power to be reported here. These findings aid in the identification of RIF resistant M. tuberculosis strains with restored fitness, which pose a greater risk of causing resistant outbreaks.

Fitness cost and compensatory evolution of drug-resistant Mycobacterium tuberculosis

Large-scale statistical analysis of Mycobacterium tuberculosis genome sequences identifies compensatory mutations associated with multi-drug resistance

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

The past, present and future of tuberculosis treatment.

Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment

Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis

Compensatory evolution in NusG improves fitness of drug-resistant M. tuberculosis

Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant <i>Mycobacterium aurum</i>

Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment

Have Compensatory Mutations Facilitated the Current Epidemic of Multidrug-Resistant Tuberculosis?

Application of Computational Methods in Understanding Mutations in Mycobacterium tuberculosis Drug Resistance

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.

Evolutionary trajectories of resistant mutants during sub-MIC antibiotic exposure

Emergence and evolution of drug-resistant Mycobacterium tuberculosis in eastern China: A six-year prospective study

Novel and reported compensatory mutations in rpoABC genes found in drug resistant tuberculosis outbreaks

Comprehensive genomic analysis of Mycobacterium tuberculosis reveals limited impact of high-fitness genotypes on MDR-TB transmission

Compensatory evolution of chromosomes and plasmids counteracts the plasmid fitness cost

The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

Biphasic adaptive evolution of antimicrobial resistance

Recent updates on drug resistance in Mycobacterium tuberculosis

Drug Resistance Tomycobacterium Tuberculosis: from the Traditional Chinese View to Modern Systems Biology